{"id":"NCT01106586","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","officialTitle":"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2011-09","completion":"2014-09","firstPosted":"2010-04-20","resultsPosted":"2012-10-22","lastUpdate":"2015-11-11"},"enrollment":708,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["HIV","HIV Infections"],"interventions":[{"type":"DRUG","name":"Stribild","otherNames":[]},{"type":"DRUG","name":"ATV","otherNames":[]},{"type":"DRUG","name":"Ritonavir","otherNames":["Norvir®"]},{"type":"DRUG","name":"FTC/TDF","otherNames":["Truvada"]},{"type":"DRUG","name":"Stribild Placebo","otherNames":[]},{"type":"DRUG","name":"ATV Placebo","otherNames":[]},{"type":"DRUG","name":"RTV Placebo","otherNames":[]},{"type":"DRUG","name":"FTC/TDF Placebo","otherNames":[]}],"arms":[{"label":"Stribild","type":"EXPERIMENTAL"},{"label":"ATV/r + FTC/TDF","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the safety and efficacy of Stribild®, a single tablet regimen (STR) containing fixed doses of elvitegravir (EVG)/cobicistat (COBI \\[GS-9350\\])/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) versus ritonavir-boosted atazanavir (ATV/r) plus the standard of care nucleoside reverse transcriptase inhibitor (NRTI) backbone FTC/TDF (Truvada®). ATV/r + FTC/TDF was selected as the active comparator for this study as it is a preferred protease inhibitor-based regimen in guidelines for the treatment of HIV-1 infected, antiretroviral treatment-naive adults.","primaryOutcome":{"measure":"The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"Stribild","deltaMin":89.5,"sd":null},{"arm":"ATV/r + FTC/TDF","deltaMin":86.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":12},"locations":{"siteCount":146,"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","France","Germany","Italy","Mexico","Netherlands","Portugal","Puerto Rico","Sweden","Switzerland","Thailand","United Kingdom"]},"refs":{"pmids":["22748590","23337366","24346640"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":353},"commonTop":["Diarrhoea","Upper respiratory tract infection","Nausea","Headache","Fatigue"]}}